Author

Gail Siu

Institution: Portola Pharmaceuticals (United States)

Observed institution: Portola Pharmaceuticals (United States)

OpenAlex ID: A5016580468

Critical role for Syk in responses to vascular injury

2011 · Patrick Andre, Toshifumi Morooka, et al. · Blood · 63

Animal Models of Thrombosis Help Predict the Human Therapeutic Concentration of PRT54021, a Potent Oral Factor Xa Inhibitor.

2006 · Keith Abe, Gail Siu, et al. · Blood · 22

Abstract 12420: Reversal of Low Molecular Weight Heparin and Fondaparinux by a Recombinant Antidote (r-Antidote, PRT064445)

2010 · Genmin Lu, Francis DeGuzman, et al. · Circulation · 10

Utilization of Telemetrized Dogs to Assess Hemodynamic Changes in a Drug Interaction Study With Verapamil and Prt054021

2007 · Keith Abe, Gail Siu, et al. · Journal of Pharmacological and Toxicological Methods

Inhibition of Prothrombinase and Not Soluble Factor Xa (fXa) Predicts Efficacy of fXa Inhibitors in an In Vivo Model of Deep Vein Thrombosis.

2006 · Suzanne Delaney, Ann Arfsten, et al. · Blood

Characterization of CG-781, a potent histone deacetylase inhibitor, as a cancer therapeutic

2005 · Zhe Cao, Kathryn E. Bass, et al. · Cancer Research

Works count: 6

Citation count: 95

H-index: 3

I10-index: 3